<DOC>
	<DOCNO>NCT00667121</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood laboratory patient receive tamoxifen may help doctor learn effect drug level tamoxifen blood . PURPOSE : This clinical trial studying level tamoxifen blood woman breast cancer woman high risk breast cancer receive tamoxifen together venlafaxine , citalopram , escitalopram , gabapentin , sertraline .</brief_summary>
	<brief_title>Tamoxifen Women With Breast Cancer Women High-Risk Breast Cancer Who Are Receiving Venlafaxine , Citalopram , Escitalopram , Gabapentin , Sertraline</brief_title>
	<detailed_description>OBJECTIVES : - To examine change plasma concentration hydroxylated metabolite , 4-hydroxy tamoxifen , endoxifen woman know high risk develop breast cancer receive selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor therapy comprise venlafaxine , citalopram hydrobromide , escitalopram oxalate , gabapentin , sertraline hydrochloride treatment hot flash , depression , medically indicated condition . - To evaluate whether genetic variant know affect activity CYP2D6 , SULT1A1 , drug metabolizing enzyme ( e.g. , UGT 's ) involve biotransformation tamoxifen citrate affect plasma concentration hydroxylated metabolite , 4-hydroxy tamoxifen endoxifen . OUTLINE : This multicenter study . Patients receive oral tamoxifen citrate concurrent selective serotonin reuptake inhibitor ( SSRI ) /serotonin-norepinephrine reuptake inhibitor ( SNRI ) therapy comprise oral venlafaxine , citalopram hydrobromide , escitalopram oxalate , sertraline hydrochloride , gabapentin 8-24 week . Treatment continue absence disease progression . Blood sample obtain baseline completion study therapy . Samples evaluate pharmacokinetic analysis determine effect SSRI/SNRI study drug plasma concentration tamoxifen metabolite . Plasma level tamoxifen citrate , N-desmethyl tamoxifen , 4-OH tamoxifen , endoxifen measure use reverse phase high performance liquid chromatography . Blood sample also analyze CYP2D6 genotyping test CYP2D6 gene variation ( i.e. , *3 , *4 , *6 , *10 , *17 , *41 ) gene encode tamoxifen-metabolizing enzyme . Additional CYP2D6 allele , include gene duplication gene deletion ( *5 ) assess .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Meets 1 follow criterion : Diagnosis invasive noninvasive breast cancer At high risk develop breast cancer Has receive tamoxifen citrate least 4 week without break either prevention adjuvant treatment invasive noninvasive breast cancer dose 20 mg/day Planning begin medical therapy one follow drug , determine physician : Venlafaxine Citalopram hydrobromide Escitalopram oxalate Sertraline hydrochloride Gabapentin Agrees continue tamoxifen citrate propose minimum study period 8 week Known CYP2D6 genotype Not know CYP2D6 poor metabolizer ( define homozygous one follow CYP2D6 null allele : *3 , *4 , *5 , *6 ) determine baseline genotype test Estrogen receptorpositive disease ( patient breast cancer ) PATIENT CHARACTERISTICS : Menopausal status specify Life expectancy â‰¥ 16 week Willing return primary site enrollment followup , include follow : Mayo Clinic Rochester Indiana University University Michigan Johns Hopkins FairfaxNorthern Virginia HematologyOncology , PC No contraindication venlafaxine , citalopram hydrobromide , escitalopram oxalate , gabapentin , sertraline hydrochloride PRIOR CONCURRENT THERAPY : See Disease Characteristics More 4 week since prior concurrent medication know inhibit CYP2D6 system</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>psychosocial effect cancer treatment</keyword>
	<keyword>breast cancer</keyword>
	<keyword>hot flash</keyword>
	<keyword>depression</keyword>
</DOC>